4.7 Review

CD123 and its potential clinical application in leukemias

Journal

LIFE SCIENCES
Volume 122, Issue -, Pages 59-64

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.lfs.2014.10.013

Keywords

CD123; Clinical application; Leukemia stem cells; Targeted therapy

Funding

  1. National Natural Science Foundation of China [81370640]
  2. Jilin Provincial Science & Technology Department [20130727041YY]

Ask authors/readers for more resources

The a chain of interleukin 3 receptor (IL-3Re alpha or CD123), together with the common 13 (beta c) subunit, forms a high-affinity IL-3R with biological function. In recent years, emerging research has found that CD123 is highly expressed on the surface of various cells (e.g., leukemia stem cells, LSCs), and it is associated with the initiation and development of many diseases, such as acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). As a novel biological marker, it has an attractive prospect in the diagnosis, targeted therapy, and evaluation of prognosis of many diseases. For these reasons, much attention has been attracted to the studies of the biological functions and potential value in the clinical application of CD123. In this review, the clinical prospects of CD123 will be discussed on the basis of information available. (C) 2014 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available